The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Development of a novel prognostic signature for colon cancer in the TOSCA trial
Alberto Puccini, MD, IRCCS Humanitas Research Hospital, Milan, Italy, shares insights from the Phase III TOSCA trial (NCT00646607), which investigated the optimal duration of FOLFOX and CAPOX chemotherapies in patients with high-risk stage II/III colon cancer. The study involved a cohort comparing patients who experienced relapse with those who did not. Through post-treatment sample sequencing after 3 to 6 months, researchers identified a novel differentially expressed gene with significant prognostic value, indicating improved disease-free survival for patients with higher gene expression levels compared to those with lower levels. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
